In a filing, AN2 Therapeutics Inc revealed its Director Readnour Robin Shane acquired Company’s shares for reported $0.16 million on Nov 19 ’24. In the deal valued at $1.04 per share,150,000 shares were bought. As a result of this transaction, Readnour Robin Shane now holds 560,073 shares worth roughly $0.75 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Readnour Robin Shane bought 50,000 shares, generating $57,870 in total proceeds. Upon buying the shares at $1.16, the Director now owns 585,073 shares.
Before that, Zakrzewski Joseph S bought 20,000 shares. AN2 Therapeutics Inc shares valued at $19,996 were divested by the Director at a price of $1.00 per share. As a result of the transaction, Zakrzewski Joseph S now holds 118,199 shares, worth roughly $0.16 million.
Leerink Partners downgraded its AN2 Therapeutics Inc [ANTX] rating to a Market perform from a an Outperform in a research note published on August 09, 2024; the price target was decreased to $1 from $5. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who decreased its forecast for the stock in early August from “an In-line” to “an Underperform”. Leerink Partners also remained covering ANTX and has increased its forecast on July 03, 2024 with a “an Outperform” recommendation from previously “Market perform” rating. JMP Securities revised its rating on April 02, 2024. It rated ANTX as “a Mkt outperform” which previously was an “a Mkt perform”.
Price Performance Review of ANTX
On Friday, AN2 Therapeutics Inc [NASDAQ:ANTX] saw its stock jump 8.94% to $1.34. Over the last five days, the stock has gained 34.00%. AN2 Therapeutics Inc shares have fallen nearly -93.46% since the year began. Nevertheless, the stocks have fallen -91.65% over the past one year. While a 52-week high of $22.22 was reached on 01/10/24, a 52-week low of $0.87 was recorded on 08/09/24. SMA at 50 days reached $1.0731, while 200 days put it at $2.1491.
Levels Of Support And Resistance For ANTX Stock
The 24-hour chart illustrates a support level at 1.2602, which if violated will result in even more drops to 1.1804. On the upside, there is a resistance level at 1.4196. A further resistance level may holdings at 1.4992. The Relative Strength Index (RSI) on the 14-day chart is 72.02, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.1843, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 24.74%. Stochastics %K at 73.13% indicates the stock is a holding.
How much short interest is there in AN2 Therapeutics Inc?
A steep rise in short interest was recorded in AN2 Therapeutics Inc stocks on 2024-10-31, dropping by 54906.0 shares to a total of 0.13 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 0.19 million shares. There was a decline of -41.11%, which implies that there is a negative sentiment for the stock.
